Last edition
News about "VISTA-inhibiting antibody"
TuHURA Biosciences Files IND for TBS-2025 in Relapsed/Refractory mutNPM1 AML
TuHURA Biosciences has filed an IND with the FDA to evaluate its VISTA-targeting antibody TBS-2025 in combination with a menin inhibitor for relapsed/refractory mutNPM1 AML.
VISTA-inhibiting Antibody | 20/02/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members